CD3-Expressing NK Cells for Bispecific Antibody Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Natural killer (NK) cells lack antigen specificity, limiting their therapeutic exploitation in cancer treatment, as they do not naturally express the CD3 receptor complex or T-cell receptors (TCRs).
Innovation Solution
NK cells are engineered to express CD3 co-receptor complexes and TCR receptor complexes, enabling them to bind with bispecific or multi-specific antibodies, allowing activation and cytotoxicity against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NK cells are engineered to express CD3 co-receptor complexes and TCR receptor complexes, then antigen specificity and therapeutic efficacy are improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent combines multiple receptor complexes (CD3 co-receptor complex and TCR receptor complex) into a single engineered NK cell system. This merging allows the NK cell to simultaneously acquire both antigen recognition capability through TCR and co-signaling capability through CD3, resolving the contradiction by integrating multiple functions into one cell type rather than using separate components
Solution Approach 2:
The engineered NK cells express both CD3 and TCR complexes, making them universally applicable to various cancer targets through different bispecific antibody configurations. The dual receptor system provides multi-functionality, allowing the same cell platform to target different antigens by simply changing the antibody component, thus improving reliability without proportionally increasing complexity
2Adaptability or versatility
If NK cells are modified to express multiple heterologous proteins including CD3 complex and TCR, then versatility with bispecific antibodies is improved, but ease of manufacture deteriorates
Solution Approach 1:
The patent performs preliminary engineering of NK cells to constitutively express both CD3 and TCR complexes before clinical use. This preliminary action creates a universal cell platform that can be paired with various bisspecific antibodies, improving versatility while concentrating the manufacturing complexity into a single upfront modification step rather than requiring complex modifications for each antibody pairing
Solution Approach 2:
The invention segments the immunotherapy system into two independent components: (1) the engineered NK cell expressing CD3 and TCR complexes, and (2) the bispecific antibody. This segmentation allows the cell manufacturing process to be standardized and decoupled from antibody development, improving ease of manufacture while maintaining versatility through modular combination of the two components
Data Source
AI summary
Embodiments of the disclosure include methods and compositions in which NK cells are modified by the hand of man to express T-cell receptor and CD3 co-receptor on NK cells that do not naturally express them. Such modified NK cells work effectively with monospecific, bispecific or multi-specific antibodies, wherein the bispecific or multi-specific antibodies are tailored to comprise anti-CD3 antibodies that bind the modified NK cells, thereby triggering signaling, activation, and cytotoxicity of target cells to which the antibodies also bind. Thus, the NK cells are specifically configured to be able to work effectively with Bispecific NK cell engagers (BiKEs) as well as Bispecific T cell Engagers (BiTEs).